Hunt AR, Nguyen V, Creuzot-Garcher CP, et al. - In this multicentre, international, database observational study, researchers compared the effectiveness of ranibizumab (0.5 mg) with aflibercept (2 mg) in the treatment of cystoid macular oedema due to branch retinal vein occlusion (BRVO) over 12 months. Three hundred twenty-two eyes initiating therapy in real-world practice over 5 years were analyzed. Despite a greater impact of aflibercept on central subfield thickness and time to first grading of inactivity, visual outcomes at 12 months in this direct comparison of ranibizumab and aflibercept for BRVO in real-world practice were generally good and comparable for the two medications.